Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes

Cancer Research

Volumn 61, Issue 17, 2001, Pages 6459-6466

  Yamada, A ^a   Kawano, K ^a   Koga, M ^a   Matsumoto, T ^a   Itoh, K ^a  

^a KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HLA A2 ANTIGEN; HLA A2402 ANTIGEN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 3; TUMOR REJECTION ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOGENICITY; LUNG ADENOCARCINOMA; MELANOMA; MONONUCLEAR CELL; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TARGET CELL;

ANIMALS; ANTIGENS, NEOPLASM; ATP-BINDING CASSETTE TRANSPORTERS; CANCER VACCINES; COS CELLS; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTE ACTIVATION; OLIGOPEPTIDES; P-GLYCOPROTEINS; PEPTIDE FRAGMENTS; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0035419399     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Human tumor antigens for cancer vaccine development
2. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
3. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognized the same HER2/neu-derived peptide
4. Identification of an immunodominant peptide of HER2/neu proto-oncogene recognized by ovarian tumor-specific cytotoxic T lymphocytes lines
5. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide
6. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes
7. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients
8. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs
9. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the cytotoxic T lymphocytes
10. Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor infiltrating lymphocytes of lung cancer
11. Biochemistry of multidrug resistance mediated by the multidrug transporter
12. Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules
13. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide sidechains
14. Human MRP3 transporter: Identification of 5′-flanking region, genomic organization and alternative splice variants
15. Biology of the multidrug resistance- associated protein, MRP
16. MRP mode of actionrole in MDR
17. A family of drug transporters: The multidrug resistance-associated proteins
18. ABC-transporters: From microorganisms to man
19. P-glycoprotein: A mediator of multidrug resistance in tumor cells
20. The GS-X pump in plant, yeast, and animal cells: Structure, function, and gene expression
21. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates
22. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump
23. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport
24. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage
25. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier
26. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein
27. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein
28. Expression of multidrug resistance protein-related genes in lung cancer: Correlation with drug response
29. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRPI), in human cancer cell lines
30. Characterization of the human ABC superfamily: Isolation and mapping of 21 new genes using the expressed sequence tags database
31. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein. MRP2, permanently expressed in human and canine cells
32. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA
33. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells
34. MRP3, an organic anion transporter able to transport anti-cancer drugs
35. Expression of multidmg resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents
36. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs
37. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs
38. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-over-expressing metastatic breast cancer refractory to chemotherapy treatment
39. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
40. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma
41. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells
42. Vaccination for malignant melanoma: Recent developments
43. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-AI
44. Interleukin-12 as an adjuvant for cancer immunotherapy
45. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
46. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine
47. Selective regulation of apoptosis: The cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway
48. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups